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tially activated by thymidine phosphorylase to 5-FU
within tumor cells. A randomized phase III clinical trial
comparing capecitabine (n  301, 1250 mg/m2/bid 

14d, q3 weeks) vs. Mayo Clinic (M)-regimen (n  301,
5-FU 425 mg/m2; LCV 20 mg/m2 d1-5, q4 weeks) re-
sulted in a superior response rate (26.6% vs. 17.9%, P 
0.013), equivalent progression-free survival (5.3 vs 4.8
months, HR (hazard ratio) 0.96), equivalent overall sur-
vival (13.2 vs 12.4 months, HR 0.91), and a superior
safety profile in terms of significantly less gastrointestinal
toxicity, neutropenia and alopecia for capecitabine. OB-
JECTIVE: To evaluate the economic consequences of oral
capecitabine vs. i.v. M-regimen administration. METHODS:
Patients were recruited from 66 centers in 8 EU-coun-
tries, Australia, New Zealand, Russia, Israel and Taiwan.
Data on number and duration of visits for drug adminis-
tration were collected during the clinical trial for all ran-
domized patients and analyzed. Cost estimates based on
publicly available statistics were used. RESULTS: For
capecitabine, one visit per cycle (every 21 days) was sched-
uled and 5 per cycle (every 28 days) for the M-regimen.
Overall, 73% of scheduled visits (for drug administra-
tion) were avoided. In all countries, with the exception of
Germany, the M-regimen was administered as an outpa-
tient treatment (96.8%–100%). In Germany 40% of all
M-regimen administrations involved overnight stays in
the hospital. Savings per patient in the range of €2,200
(UK outpatient) and €8,000 (Germany in-patient) may be
expected due to capecitabines’ oral route of administra-
tion. CONCLUSION: Oral administration of capecita-
bine substantially reduces the number of visits cancer
patients make to treating centers compared to i.v. admin-
istration (M-regimen). 73% of drug administration visits
were avoided in this phase III study. Improvements in
patient convenience and considerable savings to the
healthcare system can be realized with oral drug adminis-
tration.
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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics to determine implications
for clinical prescribing practice. METHOD: Among 1.6
million members of Merck-Medco Managed Care, L.L.C.
followed continuously between 1/1/96 and 12/31/98, we
identified all patients (N  42,510) who received a new
prescription (defined as none within the prior 12 months)
for an antidepressant in 1997 (Index AD). We observed
the time between the use of other concomitant psychotro-
pics (e.g. antipsychotics(AP)/atypicals(AP-A), anxiolytics
(ANX)/buspirone(ANX-B), sedative/hypnotics (SH) and
zolipidem (SH-Z), and miscellaneous (MISC)) in the year
prior to or after the index AD prescription. RESULTS:
14, 792 (34.8%) of AD patients used a concomitant psy-
chotropic. These patients displayed a parallel pattern in
use of all classes of concomitants: 0.2–12.2% using at
least one additional class 4 months prior to, 0.3–2.0%
same day, and 0.8–3.0% 4 months after the index antide-
pressant. However, patients were more likely to receive a
traditional antipsychotic and anxiolytic prior to the in-
dex AD, and an atypical antipsychotic and buspirone af-
ter the index AD.
Concomitant % of ADpatients
Pre Index
AD
Same
Day
Post Index
AD
AP 2.3 .7 .3 1.3
AP-A 2.4 .2 .4 1.8
ANX 21.3 12.2 2.0 7.1
ANX-B 3.7 1.5 .4 1.8
MISC 2.6 .7 .3 .8
SH 5.7 3.0 .4 2.3
SH-Z 9.0 4.4 .7 3.0
CONCLUSION: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre and post index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. All
classes of concomitant psychotropics revealed a similar
general pattern: a steady increase in the 4 months prior to
an index AD, a peak on the index AD date, and a taper-
ing over the next 4 months. We speculate that continuing
medical education of physicians may be contributing to a
decrease in the misuse of benzodiazepines and sedative/
hypnotics.
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OBJECTIVES: To assess the risk of diabetes among pa-
tients undergoing treatment with risperidone vs olanza-
pine. A series of case reports had previously associated
olanzapine use with the development of hyperglycemia,
diabetes, and diabetic ketoacidosis. METHODS: Two
cohorts totaling 34,713 patients were identified from the
Quebec Medicare database between January 1997 and
31st December 1999. One cohort consisted of patients
who had at least one prescription for olanzapine during
that period (n  19,779) and the other of patients receiv-
ing risperidone but not olanzapine (n  14,934). In ei-
ther case, patients with a diagnosis of diabetes (defined as
either a recorded ICD9 250.0 to 250.93 or a prescription
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for insulin or an oral hypoglycemic agent) before begin-
ning anti-psychotic therapy were excluded. New diabetes
diagnoses after the first antipsychotic prescription were
tabulated until 31st December 1999; censoring occurred
at this date, or the diagnosis of diabetes or at the last ser-
vice date if there was no record of using any services dur-
ing the last six months. Crude hazard ratios and propor-
tional hazards analyses were carried out. RESULTS: 336
patients developed diabetes after being prescribed olanza-
pine, and 220 after risperidone, a crude hazard ratio of
1.10 (95% CI 0.90 to 1.35). When correcting for severe
imbalances in age and gender using proportional hazards
analysis, the hazard ratio increased to 1.22 (95% CI 1.02
to 1.45). After also adjusting for the duration of olanza-
pine exposure, the first three months of olanzapine treat-
ment was associated with the highest risk of diabetes,
hazard ratio 1.91 (95% CI 1.42 to 2.58). CONCLU-
SIONS: Olanzapine was associated with an increased risk
of developing diabetes compared to risperidone. More
studies are required to confirm the association of olanza-
pine with hyperglycemia and to identify the patient
groups at highest risk of developing diabetes.
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Major costs associated with depression are related to
work loss and reduced productivity. Since treatment can
improve functioning in these areas, economic evaluations
of new antidepressants should consider their impact on
productivity costs. However, clinical trials do not gener-
ally measure effects of pharmacotherapy on disability
days but rather use patient or clinician assessments of
functioning (e.g., HAM-D). We have developed (and pre-
viously reported) a method using HAM-D scores to esti-
mate disability days for comparing economic impact of
different treatments. OBJECTIVES: The methodology is
based upon theoretical considerations. In order to strengthen
its value for practical applications, the current study as-
sesses the predictive validity of the proposed methodol-
ogy. METHODS: As patients using antidepressants make
clinical improvements, the methodology predicts associ-
ated gains in productivity. We compared the gains pre-
dicted for clinical trial patients to actual observations
from a real-world setting. For this purpose, we used data
reported by Treglia and Neslusan at ISPOR’s 5th annual
international meeting, and derived from a commercial
health care database, examining patterns of absenteeism
for 716 employees newly diagnosed with depression from
1994–1996. RESULTS: The observed number of medical
absences averaged 14.0 days during the first 2 months af-
ter pharmacotherapy began and 7.5 during the next 2
months. In comparison, our new methodology predicted
12.4 days during the 2 months of initial treatment and
5.2 days in the following 2-month period. CONCLU-
SIONS: The new methodology predicted similar absen-
teeism for clinical trial patients as that observed among
employees. The different levels of absenteeism are likely
due to differences between the two groups (i.e., clinical
trial versus real world). Since our results support the pre-
dictive validity of the methodology, we are proceeding to
use it conditional upon further validation involving si-
multaneous measurement of both HAM-D scores and
disability days in a sample of patients with depression.
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OBJECTIVE: To assess patient quality-of-life and utili-
ties for health states associated with different levels of
amyotrophic lateral sclerosis (ALS) severity. METHODS:
A structured interview was conducted with 77 patients,
in 2 UK centers, covering four different clinical stages of
ALS severity. Patients completed a disease specific health
status measure (ALSAQ-40), a generic health status mea-
sure (EuroQol EQ-5D), visual analog scale (VAS) rating
of current health and a standard gamble (SG) exercise to
provide health state utilities for their own health state.
RESULTS: The ALSAQ-40 was sensitive to disease sever-
ity, with scores for later stage disease states showing a
lower level of patient rated health status than the scores
for early stage disease states. Patients’ mean VAS rating
of their own health ranged from 0.74 (95% CI: 0.64–
0.85) for stage 1 (early) disease severity (n  15), to 0.37
(95% CI: 0.29–0.46) for stage 4 (late stage) disease sever-
ity (n  19). The mean VAS rating for the entire group
was 0.55 (95% CI: 0.50–0.60), (n  76). Utilities elicited
via SG were systematically higher than VAS scores and
ranged from a mean of 0.79 (95% CI: 0.71–0.88) for
stage 1 disease severity (n  15) to a mean of 0.45 (95%
CI: 0.28–0.61) for stage 4 disease severity (n  19). The
mean SG score for the entire group was 0.65 (95% CI:
0.58–0.71), (n  76). The EQ-5D was not sensitive to the
different levels of disease severity. CONCLUSIONS: This
study demonstrates that it is feasible and practical to ob-
tain ALS patients’ valuations of their current health state.
VAS and SG values associated with each of the 4 stages
of disease severity fell as disease severity progressed
through stages 1 to 4. ALS patients’ rating of their health
state and the SG scores provide evidence that patients
value their health-related quality-of-life highly, even in
cases where health status is very poor.
